Tomahawk, WI 12/04/2013 (BasicsMedia) – It is not everyday that the future of an entire company hangs on a single product. Unfortunately, that is what Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has to worry about since its Leukemia drug, Iclusig, was put on hold and is no longer being sold. The pharmaceutical giant had no option than to take such a step after the Food and Drugs Administration evaluated the drug and found it guilty of causing blood clots in a number of patients. The blood clots were a threat to life, and FDA recommended that ARIA conduct more tests to eliminate this fear.

ARIA’s Iclusig Carries Life-Threatening Risks

In the pharmaceutical industry, such seemingly simple or ordinary mistakes can be costly. The company is now forced to wait for ages, before it gets a date with FDA yet again. Until the meeting with FDA takes place, and Iclusig is tested and proven harmless with regard to the allegations leveled against it, there is no way in which its sales will be sanctioned. The reason Aria’s future is now in doubt, is because it does not have any other drug that FDA has approved for production and sale. Iclusig was the only drug that enjoyed this rare distinction.

Initially, Iclusig was to be used by patients that had undergone some form of therapy. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) now hoped to spread the usage of this drug to people who were yet to undergo any form of therapy. FDA later came up to say that twenty four percent of people going through a form of therapy known as PACE, hade developed complications after being put on Iclusig, and until the actual cause of the problem was identified, the drug had to be withdrawn from the drug stores, and further production brought to a halt. As to how long this process will last, that is hard to tell.

Common Side Effects Associated with Iclusig

Some of the side effects the drug was thought to have caused in the patients using it include blood clots, loss of blood flow to the brain and heart, heart attacks and stroke. The loss of blood flow to the brain and heart could not be resolved in any other way except through surgical procedures. This presented more problems to patients bearing in mind that the costs of treatment for their chronic form of leukemia was already eating deeper into their finances. Not only that, but also surgical procedure was risky to the patients who were already under intense treatment.

The drug has already been approved, but the only thing that hangs in the balance is its sale to patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been allowed to continue with the trial of this drug until it meets all safety requirements and is deemed not to carry any side effect. As long as it is not a threat to lives of patients using it, FDA will approve its sale to the public, and list it as one of the drugs allowed for use by people suffering from chronic form of leukemia. There was a time when Iclusig was reported to possess a favorable risk benefit profile but this has now changed substantially.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.